Lucemyra: FDA Approves New Medication-Assisted Treatment

Lucemyra has been on the market in the UK to assist with opioid withdrawal symptoms for about twenty years, but its use in the US has only just been approved. The FDA cleared the drug last Wednesday via fast-track to give American doctors another tool for fighting the opioid epidemic. Lucemyra alone is not to be considered treatment for opioid use disorder, the FDA says. However, clinical trials prove that it can reduce the severity of withdrawal symptoms that patients experience when they cease opioid use completely. This can give a person with an opioid use disorder a lifeline to help them get clean once and for all. Combined with therapy, 12-step programs and other tools, Lucemyra can help people find their way to recovery without the torment of many withdrawal symptoms. FDA Commissioner Dr. Scott Gottlieb says that this makes the drug an important tool that warranted quick approval. "The physical symptoms of opioid withdrawal can be one of the biggest barriers for patients seeking help and ultimately…

Continue Reading